Loading clinical trials...
Loading clinical trials...
A Pragmatic Phase II Study Evaluating Tolerability in Prostate Cancer Patients Treated With Abiraterone + Prednisone or Darolutamide
Conditions
Interventions
Abiraterone
Biospecimen Collection
+2 more
Locations
1
United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Start Date
November 9, 2023
Primary Completion Date
November 1, 2026
Completion Date
May 1, 2027
Last Updated
March 13, 2026
NCT04693377
NCT05691465
NCT04550494
NCT07073794
NCT06205316
NCT04134260
Lead Sponsor
University of California, Davis
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions